Designed multiple ligands. An emerging drug discovery paradigm

J Med Chem. 2005 Oct 20;48(21):6523-43. doi: 10.1021/jm058225d.
No abstract available

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / chemistry
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Anti-Allergic Agents / chemistry
  • Anti-Allergic Agents / pharmacology
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology
  • Antidepressive Agents / chemistry
  • Antidepressive Agents / pharmacology
  • Antihypertensive Agents / chemistry
  • Antihypertensive Agents / pharmacology
  • Antipsychotic Agents / chemistry
  • Antipsychotic Agents / pharmacology
  • Chemistry, Pharmaceutical / trends*
  • Dopamine D2 Receptor Antagonists
  • Drug Design*
  • Humans
  • Ligands*
  • Metabolic Diseases / drug therapy
  • Peroxisome Proliferator-Activated Receptors / drug effects
  • Receptors, Histamine H1 / drug effects
  • Selective Serotonin Reuptake Inhibitors / chemistry
  • Selective Serotonin Reuptake Inhibitors / pharmacology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Anti-Allergic Agents
  • Anti-Inflammatory Agents, Non-Steroidal
  • Antidepressive Agents
  • Antihypertensive Agents
  • Antipsychotic Agents
  • Dopamine D2 Receptor Antagonists
  • Ligands
  • Peroxisome Proliferator-Activated Receptors
  • Receptors, Histamine H1
  • Serotonin Uptake Inhibitors